Method: A retrospective snap shot audit of 33 patients who were discharged from ED in 2017/18 was undertaken. Drug anaphylaxis N= 5 (16%) was excluded as an adrenaline auto injecting device is not usually indicated. The content of patient referrals, with and without an ADC and their electronic discharge summary were audited against the ADC criteria.
Results: Patients discharged from ED whose referral contained the ADC sticker scored significantly better compliance with discharge criteria relating to allergen avoidance advice N=6 (30%), adrenaline auto-injecting prescription N=12 (60%) inclusive of demonstration N=6 (30%) and anaphylaxis action plan N=14 (70%).
Case-note alert remains concerning low N=1 (5%).
The discharge management noted on the referral form and electronic discharge summary were inconsistent. When assessed for compliance with the ADC the electronic discharge summary content was deficient in documentation of discharge actions.
Conclusion:
The ADC sticker is a simple checklist for ED staff to effectively discharge patients at risk of anaphylaxis. Documentation of discharge care on referrals assists in triaging of referrals and risk management of patients whilst they are waiting for specialist appointments.
This audit provides evidence that a simple organized tool which aligns with current evidenced based anaphylaxis discharge criteria has a role within the clinical setting.
Combining an electronic patient ED referral/discharge summary which is inclusive of an ADC could further improve patient care at discharge. Background: Epidemiological studies conducted in America and Europe have reported a wide prevalence range of 0.5-7% for systemic reactions to insect stings in the general population. A recent Australian study using national hospital data from 2001 to 2013 identified that deaths due to anaphylaxis following insect envenomation occurred at a rate of 0.16 per 100 000 persons, with higher rates in males and in South Australia. However, there remains a lack of data regarding the epidemiology of insect allergy in Australia and thus we sought to identify the frequency of insect allergy within South Australia.
Methods: A prospective cross-sectional study was performed between September to December 2017, involving face-to-face surveys of South Australian community members. Subjects were selected via randomized stratified sampling. The survey included questions regarding reactions to insect stings, including local or systemic reactions and hospitalisation.
Results: A total of 2,977 subjects (57.0% response rate) responded to the survey, with the majority residing in a metropolitan area (81.7%). 754 (25.3%) of subjects reported a history of reactions to insect stings, with 677 respondents (22.7%) describing large local reactions. 116 (3.5%) subjects reported experiencing systemic symptoms such as difficulty breathing, vomiting and diarrhoea, or loss of consciousness. Nonmetropolitan respondents had a statistically significant increased rate of insect sting systemic reactions compared to metropolitan residents (5.6% vs 2.7%). Overall, females reported a higher rate of reaction to insect stings (27% vs 22%), although there was no difference between sexes for systemic reactions. No statistically significant differences were identified between age or country of birth for reactions to insect stings.
Conclusion: 3.5% of surveyed individuals reported a history consistent with a systemic reaction to an insect sting, with a higher frequency in nonmetropolitan residents but no statistically significant difference according to age or sex. The aim was to provide accessible, consistent, accurate and easy to follow information in an anaphylaxis emergency, and therefore reduce fatal anaphylaxis. These plans are used throughout Australia and New Zealand, the only countries in the world that have only one action plan for anaphylaxis that is completed by medical and nurse practitioners. ASCIA Action Plans for Anaphylaxis are regularly reviewed and updated, and most changes have been based on published data and coronial inquiry recommendations. In 2018 a major update of ASCIA Action Plans for Anaphylaxis included the development of a generic version, which can be used with any brand of adrenaline (epinephrine) autoinjector.
P28 DEVELOPMENT OF A GENERIC ASCIA ACTION PLAN FOR ANAPHYLAXIS
Method: In 2018 several updates were made to the EpiPen ® versions of the ASCIA Action Plan for Anaphylaxis after an extensive consultation period with the ASCIA membership. A generic version was developed in parallel, which does not include any brand specific adrenaline autoinjector instructions. To ensure accuracy and consistency of information, ASCIA anaphylaxis e-training courses and other ASCIA resources were also updated.
Changes to ASCIA Action Plans: The main changes are:
• New generic versions can be used with any brand of adrenaline autoinjector, with no mention of brand names or brand specific instructions.
• To reduce the risk of prescribing or dispensing the incorrect dose of adrenaline autoinjector, ASCIA prescribing guidelines are now included on version of the plans: Adrenaline autoinjectors (300mcg) are prescribed for children over 20kg and adults; Adrenaline autoinjectors (150mcg) are prescribed for children 10-20kg.
• To minimise the risk of inappropriate treatment and prevent allergic reactions to ticks, the following updated information is included on each plan "For tick allergy seek medical help or freeze tick and let it drop off".
• As a result of new research data, the following wording has been added to each plan;If adrenaline is accidentally injected (e.g. into a thumb) phone your local poisons information centre. Continue to follow this action plan for the person with the allergic reaction.
Conclusion:
In an anaphylaxis emergency, ASCIA Action Plans for Anaphylaxis provide easy to follow information which is consistent and accurate. The generic or EpiPen versions of the ASCIA Action Plan for Anaphylaxis should be completed by a medical or nurse practitioner, for each patient with prescribed adrenaline autoinjectors. The generic versions can be used with any brand of adrenaline autoinjectors. 
